H.C. Wainwright raised the firm's price target on TG Therapeutics to $70 from $60 and keeps a Buy rating on the shares after the company reported Q1 earnings. The firm, which is increasing its U.S. Briumvi and total revenue estimates, cites both increased estimates and greater confidence in 2026 performance for its raised target.
